Proteopedia - User contributions [en]

Clostridium botulinum neurotoxin serotype A light chain

2018-03-29T09:01:19Z

Xavier Hartmann:

==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC complex with Zn+2 ions (PDB code [[3bon]])' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref> (see '''Figure 2''')
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>

The light chain of '' Clostridium botulinum '' neurotoxin serotype A presents several typical structures.
*The polypeptide forms 11 α-helices (we can notice a kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
*We can also find three 3-10 helices (<scene name='60/604485/H3/2'>H3</scene>, <scene name='60/604485/H13/1'>H13</scene>, <scene name='60/604485/H14/1'>H14</scene>)
*There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>
* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

=== Mechanism & Catalytic site ===
[[Image:BoNT.jpg|thumb|'''Figure 2 :''' Global aspect of C.botulinum neurotoxin serotype A (made using PyMol and modified with Inkscape by Xavier Hartmann) ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.

It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release, inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 3 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 3''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, started to work on the use of the botulinum toxin in therapeutic process.
First, they tried to treat strabismus and in the late 1970s the neurotoxin was used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated in the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the relaxation ok the muscles.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a period of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)

==References==
<references />

Clostridium botulinum neurotoxin serotype A light chain

2015-07-18T09:02:43Z

Xavier Hartmann:

==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref> (see '''Figure 2''')
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>

The light chain of '' Clostridium botulinum '' neurotoxin serotype A presents several typical structures.
*The polypeptide forms 11 α-helices (we can notice a kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
*We can also find tree 3-10 helices (<scene name='60/604485/H3/2'>H3</scene>, <scene name='60/604485/H13/1'>H13</scene>, <scene name='60/604485/H14/1'>H14</scene>)
*There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>
* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

=== Mechanism & Catalytic site ===
[[Image:BoNT.jpg|thumb|'''Figure 2 :''' Global aspect of C.botulinum neurotoxin serotype A (made using PyMol and modified with Inkscape by Xavier Hartmann) ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.

It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release, inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 3 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 3''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, started to work on the use of the botulinum toxin in therapeutic process.
First, they tried to treat strabismus and in the late 1970s the neurotoxin was used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated in the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the relaxation ok the muscles.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a period of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)

==References==
<references />

Sandbox Reserved 966

2015-07-18T08:44:02Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref> (see '''Figure 2''')
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>

The light chain of '' Clostridium botulinum '' neurotoxin serotype A presents several typical structures.
*The polypeptide forms 11 α-helices (we can notice a kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
*We can also find tree 3-10 helices (<scene name='60/604485/H3/2'>H3</scene>, <scene name='60/604485/H13/1'>H13</scene>, <scene name='60/604485/H14/1'>H14</scene>)
*There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>
* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

=== Mechanism & Catalytic site ===
[[Image:BoNT.jpg|thumb|'''Figure 2 :''' Global aspect of C.botulinum neurotoxin serotype A (made using PyMol and modified with Inkscape by Xavier Hartmann) ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.

It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release, inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 3 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 3''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, started to work on the use of the botulinum toxin in therapeutic process.
First, they tried to treat strabismus and in the late 1970s the neurotoxin was used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated in the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the relaxation ok the muscles.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a period of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)
== Contributors ==
Xavier Hartmann and Rémi Pelletier

==References==
<references />

Sandbox Reserved 966

2015-07-18T08:42:50Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref> (see '''Figure 2''')
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>

The light chain of '' Clostridium botulinum '' neurotoxin serotype A presents several typical structures.
*The polypeptide forms 11 α-helices (we can notice a kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
*We can also find tree 3-10 helices (<scene name='60/604485/H3/2'>H3</scene>, <scene name='60/604485/H13/1'>H13</scene>, <scene name='60/604485/H14/1'>H14</scene>)
*There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>
* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

=== Mechanism ===
[[Image:BoNT.jpg|thumb|'''Figure 2 :''' Global aspect of C.botulinum neurotoxin serotype A (made using PyMol and modified with Inkscape by Xavier Hartmann) ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.

It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release, inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 3 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]

===Catalytic site ===
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 3''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, started to work on the use of the botulinum toxin in therapeutic process.
First, they tried to treat strabismus and in the late 1970s the neurotoxin was used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated in the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the relaxation ok the muscles.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a period of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)
== Contributors ==
Xavier Hartmann and Rémi Pelletier

==References==
<references />

Sandbox Reserved 966

2015-07-18T08:26:35Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref> (see '''Figure 2''')
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>

The light chain of '' Clostridium botulinum '' neurotoxin serotype A presents several typical structures.
*The polypeptide forms 11 α-helices (we can notice a kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
*We can also find tree 3-10 helices (<scene name='60/604485/H3/2'>H3</scene>, <scene name='60/604485/H13/1'>H13</scene>, <scene name='60/604485/H14/1'>H14</scene>)
*There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>
* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene> (we can notice the kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

=== Mechanism ===
[[Image:BoNT.jpg|thumb|'''Figure 2 :''' Global aspect of C.botulinum neurotoxin serotype A (made using PyMol and modified with Inkscape by Xavier Hartmann) ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.

It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release, inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 3 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]

===Catalytic site ===
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 3''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, started to work on the use of the botulinum toxin in therapeutic process.
First, they tried to treat strabismus and in the late 1970s the neurotoxin was used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated in the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the relaxation ok the muscles.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a period of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)
== Contributors ==
Xavier Hartmann and Rémi Pelletier

==References==
<references />

Sandbox Reserved 966

2015-07-18T08:23:24Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref> (see '''Figure 2''')
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>

The light chain of '' Clostridium botulinum '' neurotoxin serotype A presents several typical structures.
*The polypeptide forms 11 α-helices (we can notice a kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
*We can also find tree 3-10 helices
*There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>
* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene> (we can notice the kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

=== Mechanism ===
[[Image:BoNT.jpg|thumb|'''Figure 2 :''' Global aspect of C.botulinum neurotoxin serotype A (made using PyMol and modified with Inkscape by Xavier Hartmann) ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.

It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release, inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 3 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]

===Catalytic site ===
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 3''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, started to work on the use of the botulinum toxin in therapeutic process.
First, they tried to treat strabismus and in the late 1970s the neurotoxin was used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated in the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the relaxation ok the muscles.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a period of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)
== Contributors ==
Xavier Hartmann and Rémi Pelletier

==References==
<references />

Sandbox Reserved 966

2015-01-10T02:27:19Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref> (see '''Figure 2''')
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene> (we can notice the kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

=== Mechanism ===
[[Image:BoNT.jpg|thumb|'''Figure 2 :''' Global aspect of C.botulinum neurotoxin serotype A (made using PyMol and modified with Inkscape by Xavier Hartmann) ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.

It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release, inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 3 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]

===Catalytic site ===
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 3''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, start to work on the use of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a period of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)
== Contributors ==
Xavier Hartmann and Rémi Pelletier

==References==
<references />

Sandbox Reserved 966

2015-01-10T02:23:35Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref> (see '''Figure 2''')
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene> (we can notice the kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here due to the condition for getting the crystal structure.

=== Mechanism ===
[[Image:BoNT.jpg|thumb|'''Figure 2 :''' Global aspect of C.botulinum neurotoxin serotype A (made using PyMol and modified with Inkscape by Xavier Hartmann) ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.
It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 3 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]

===Catalytic site ===
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 3''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, start to work on the use of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a periode of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)
== Contributors ==
Xavier Hartmann and Rémi Pelletier

==References==
<references />

Sandbox Reserved 966

2015-01-10T02:21:14Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref> (see '''Figure 2''')
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene> (we can notice the kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here du to the condition of obtention of the crystal structure.

=== Mechanism ===
[[Image:BoNT.jpg|thumb|'''Figure 2 :''' Global aspect of C.botulinum neurotoxin serotype A (made using PyMol and modified with Inkscape by Xavier Hartmann) ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.
It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 3 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]

===Catalytic site ===
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 3''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, start to work on the use of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a periode of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)
== Contributors ==
Xavier Hartmann and Rémi Pelletier

==References==
<references />

Sandbox Reserved 966

2015-01-10T02:13:29Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref>
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene> (we can notice the kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here du to the condition of obtention of the crystal structure.

=== Structural highlights ===
== Mechanism ==
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.
It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 2 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]

*Catalytic site :
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 2''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, start to work on the use of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a periode of use.

== Related Structures ==
* Structure of the C. botulinum neurotoxin serotype A apo-enzyme [http://www.rcsb.org/pdb/explore.do?structureId=3bok 3BOK] (light chain)
* Structure of the C. botulinum neurotoxin serotype A with an inhibitory peptide bound [http://www.rcsb.org/pdb/explore.do?structureId=3boo 3BOO] (light chain)
* Crystal structure of botulinum neurotoxin serotype A [http://www.rcsb.org/pdb/explore/explore.do?structureId=3BTA 3BTA] (whole toxin)
== Contributors ==
Xavier Hartmann and Rémi Pelletier

==References==
<references />

File:BoNT.jpg

2015-01-10T02:13:23Z

Xavier Hartmann:

== Licensing ==
{{PD-self}}

Sandbox Reserved 966

2015-01-10T01:41:43Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref>
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene> (we can notice the kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here du to the condition of obtention of the crystal structure.

=== Structural highlights ===
== Mechanism ==
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.
It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 2 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]

*Catalytic site :
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 2''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, start to work on the use of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a periode of use.

== Contributors ==
Xavier Hartmann and Rémi Pelletier

==References==
<references />

Sandbox Reserved 966

2015-01-10T01:38:59Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref>
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene> (we can notice the kink formed by <scene name='60/604485/Thr101/1'>Thr101</scene>, who may interact with an H from the N of Gly104)
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here du to the condition of obtention of the crystal structure.

=== Structural highlights ===
== Mechanism ==
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.
It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 2 :''' Enzymatic mechanism of BoNT/A. Steps are numbered (made using ChemDraw Ultra by Xavier Hartmann) ]]

*Catalytic site :
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 2''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, start to work on the use of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a periode of use.

==References==
<references />

Sandbox Reserved 966

2015-01-10T01:23:32Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref>
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene> (we can notice the kink formed by
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> that are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

The Cys429 involved in the disulfide bond between the HC and the LC can't be shown here du to the condition of obtention of the crystal structure.

=== Structural highlights ===
== Mechanism ==
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.
It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 2 :''' Enzymatic mechanism of BoNT/A (made using ChemDraw Ultra by Xavier Hartmann ]]

*Catalytic site :
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''

The enzymatic reaction is shown on '''Figure 2''' and takes place at the <scene name='60/604485/Catalytic_site/2'>catalytic site</scene>. As it is developed on the scheme, a lot of residues and molecules of water are involved.

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco ophthalmologist, Alan Scott, start to work on the use of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinum toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected locally to paralyse targeted muscles and reduce wrinkles temporally<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BoNT/A is used against cervical dystonia. But it can become inefficient after a periode of use.

==References==
<references />

Sandbox Reserved 966

2015-01-10T00:50:16Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref>
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene>
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> most of them are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

=== Structural highlights ===
== Mechanism ==
[[Image:Mecanismefinal.jpg|thumb|'''Figure 2 :''' Enzymatic mechanism (made using ChemDraw Ultra by Xavier Hartmann ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.
It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site in red), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.

*Catalytic site :
At first glance the tunnel for the access of the substrate is clearly visible <scene name='60/604485/Catalytic_site_view/1'>view of the catalytic site</scene> ''(unfortunately the representation of the surface is bugged, catalytic site can't be displayed in another color)''
<scene name='60/604485/Catalytic_site/2'>Catalytic site</scene>

== Therapeutic applications ==
In the late 1960s, Edward Schantz and a San Francisco opthalmologist, Alan Scott, start to work on the use of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinium toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected localy to paralyse targeted muscles and reduce wrinkles temporaly<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BTX-A is used against cervical dystonia. But it can become inefficient after a periode of use.

==References==
<references />

Sandbox Reserved 966

2015-01-10T00:28:33Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref>
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene>
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> most of them are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

=== Structural highlights ===
== Mechanism ==
[[Image:Mecanismefinal.jpg|thumb|'''Figure 2 :''' Enzymatic mechanism (made using ChemDraw Ultra by Xavier Hartmann ]]
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.
It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A cleaves a peptide bond of a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page''] (involved in the phenomenon of vesicle fusion) and especially the Gln197 - Arg198 peptide bond of SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 ''Wikipedia page''] blocking the release of neurotransmitter release inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQAN[[QR]]ATKML, cleavage site underlined), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides.<ref>PMID: 18457419</ref> Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.

<scene name='60/604485/Catalytic_site/2'>Catalytic site</scene>

== Therapeutic applications ==
In the late 1960s, a Edward Schantz and a San Francisco opthalmologist, Alan Scott, start to work on the using of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinium toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected localy to paralyse targeted muscles and reduce wrinkles temporaly<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BTX-A is used against cervical dystonia. But it can become inefficient after a periode of use.

==References==
<references />

Sandbox Reserved 966

2015-01-10T00:23:00Z

Xavier Hartmann:

{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref>
The ''Clostridium botulinum'' neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
The Ramachandran diagram (see '''Figure 1''') shows the distribution of the residues in the protein. Amino acids are globally in favored regions.
[[Image:ramachandran3BON.png|thumb|'''Figure 1 :''' Ramachandran diagram of C.botulinum neurotoxin serotype A light chain (made using Python by Rémi Pelletier)]]

The <scene name='60/604485/Secondary_structure/1'>Secondary structure</scene> of BoNT/A-LC<ref>http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1</ref>
*The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
**Helix 1 : <scene name='60/604485/H1/2'>H1</scene>
**Helix 2 : <scene name='60/604485/H2/1'>H2</scene>
**Helix 4 : <scene name='60/604485/H4/1'>H4</scene>
**Helix 5 : <scene name='60/604485/H5/1'>H5</scene>
**Helix 6 : <scene name='60/604485/H6/1'>H6</scene>
**Helix 7 : <scene name='60/604485/H7/1'>H7</scene>
**Helix 8 : <scene name='60/604485/H8/1'>H8</scene>
**Helix 9 : <scene name='60/604485/H9/1'>H9</scene>
**Helix 10 : <scene name='60/604485/H10/1'>H10</scene>
**Helix 11 : <scene name='60/604485/H11/1'>H11</scene>
**Helix 12 : <scene name='60/604485/H12/1'>H12</scene>

* It also has three 3-10 helices :
**Helix 3 : <scene name='60/604485/H3/2'>H3</scene>
**Helix 13 : <scene name='60/604485/H13/1'>H13</scene>
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene>

* There are several <scene name='60/604485/Sheets/1'>β sheets </scene> most of them are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene>

* An interesting structure is also a typical <scene name='60/604485/Betaturn/1'>β-turn</scene> : indeed the chain makes a sharp reversal by 180° within 4 residues, moreover Cα from the ''i'' residue and the Cα from the ''i+3'' residue are separated by less than 7 angstroms.

=== Structural highlights ===
== Mechanism ==
The neurotoxin inactivates neurotransmitter release owing to its metalloprotease activity. It targets the presynaptic membrane of peripheral nerve terminals using a binding mode based on the use of two independent receptors: a polysialoganglioside (PSG) and a protein receptor in the lumen of synaptic vesicles<ref>PMID: 23239349</ref>. ''Clostridium botulinum'' neurotoxin is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). The heavy chain presents the PSG binding domain and is therefore implied in the entry of the neurotoxin in the nerve cell thanks to vesicles; then the disulfide bond is broken and the light chain is released.
It is the light chain that carries the metalloprotease activity. Neurotoxin serotype A targets a protein belonging to the SNARE family [http://en.wikipedia.org/wiki/SNARE_(protein) ''Wikipedia page on what a SNARE protein is''] (involved in the phenomenon of vesicle fusion and especially the protein SNAP-25 [http://en.wikipedia.org/wiki/SNAP25 Wikipedia page] blocking the release of neurotransmitter release inducing paralysis. The BoNT LCs are remarkable among proteases for the extremely long substrates required for efficient proteolysis. With a minimum substrate of 17 amino acids (SNKTRIDQANQRATKML, cleavage site underlined), the BoNT/A protease accepts shorter peptide substrates than any of the other serotypes. In comparison, other microbial metalloproteases have been found to have activity against substrates as short as dipeptides. Structural and biochemical data on the BoNT/ A-LC suggest that most of the specific interactions between the enzyme and the SNAP-25 substrate occur at sites remote from the active site. Indeed, the only amino acid within the cleavage sequence that is required for efficient proteolysis is the P1′ Arg198 <ref>PMID:15592454</ref>.
[[Image:Mecanismefinal.jpg|thumb|'''Figure 2 :''' Enzymatic mechanism (made using ChemDraw Ultra by Xavier Hartmann ]]
<scene name='60/604485/Catalytic_site/2'>Catalytic site</scene>

== Therapeutic applications ==
In the late 1960s, a Edward Schantz and a San Francisco opthalmologist, Alan Scott, start to work on the using of the botulinum toxin in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref>
=== Hyperhidrosis and CHARGE syndrome ===
We can now treat excessive sweating with botulinium toxin <ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
=== Cosmetic ===
Non-lethal amount of botulinum toxin can be injected localy to paralyse targeted muscles and reduce wrinkles temporaly<ref>http://rms.medhyg.ch/numero-200-page-870.htm</ref> (5 to 6 months).
=== Blepharospesm, nystagmus, torticollis and strabismus ===
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
=== Cervical dystonia ===
BTX-A is used against cervical dystonia. But it can become inefficient after a periode of use.

==References==
<references />

Sandbox Reserved 966

2015-01-09T23:57:05Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T23:20:15Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T23:11:52Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T23:10:09Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T22:56:52Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T22:37:13Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T22:18:22Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T22:16:58Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T22:11:28Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T22:07:08Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T14:11:47Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T13:54:39Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T13:17:23Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T13:04:43Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T13:02:23Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T11:47:53Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T11:44:33Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T11:39:25Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-09T11:38:51Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-08T19:45:51Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-08T17:56:20Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-08T17:04:57Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-08T16:45:43Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-08T07:23:29Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-04T21:40:01Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-04T20:05:42Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-04T20:01:26Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-04T19:56:14Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-04T17:11:48Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-04T16:24:50Z

Xavier Hartmann:

File:Mecanismefinal.jpg

2015-01-04T16:23:58Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-04T16:16:59Z

Xavier Hartmann:

Sandbox Reserved 966

2015-01-04T16:15:25Z

Xavier Hartmann:

[[Image:Example.jpg]]{{Sandbox_ESBS}}
==Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound==
<StructureSection load='3BON' size='340' side='right' caption='Caption for this structure' scene='60/604485/General_introduction/2'>
The Clostridium botulinum neurotoxin produced by the bacteria ''Clostridium botulinum'' (and some strains of ''Clostridium butyricium'' and ''Clostridium baratii'') is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond <ref>PMID: 24975322</ref>
The "Clostridium botulinum" neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. <ref>PMID: 18457419</ref>

== Structure ==
===Global aspect===
BoNT/A-LC presents <scene name='60/604485/Secondary_structure/1'>secondary structure</scene>
{|
| [[Image:ramachandran3BON.png|left|200px]]
|}
[[Image:Mecanisme3BON.jpg]]
=== Structural highlights ===
== Mechanism ==

== Therapeutic applications ==
In the late 1960s, a Edward Schantz and a San Francisco opthalmologist, Alan Scott, start to work on the using of the botulinum toxine in therapeutic process.
First, they try to treat strabismus and in the late 1970s the neurotoxine is used in many therapeutic applications.
=== hyperhidrosis ===
=== Cosmetic ===
=== Blepharospesm and strabismus ===
=== Torticollis ===
=== UMN syndrome ===
=== Chronic migraine ===
=== Cervical dystonia ===